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mild cognitive impairment (MCI) assuming a hypothetical disease-modifying Alzheimer’s disease
(AD) treatment.
Methods: A decision model compared current practice to a perfect biomarker and to two strategies
positioning CSF as add-on test when current practice concluded the presence or absence of AD.
Results: The simulated MCI population was aged on average 68.3 and 49% had AD. The room for
improvement by the perfect CSF test was 0.39 quality adjusted life years,V33,622 ($43,372) savings,
2.0 potential beneficial treatment years, and 1.3-year delay in dementia conversion.
Discussion: The results indicated more potential benefit from a biomarker positioned to verify sub-
jects who are not expected to have AD (i.e., to prevent undertreatment) rather than to verify subjects
expected to have AD (prevent overtreatment). Sensitivity analyses explored different CSF positions.
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With a global prevalence of 35.6 million and a corre-
sponding economic impact of US $604 billion dementia
has a substantial burden on societies worldwide [1,2].
There has been a growing interest in biomarkers in
cerebrospinal fluid (CSF), positron emission tomography,
and magnetic resonance imaging [3] to identify Alzheimer’s
disease (AD) pathology in patients with the predementiathor. Tel.:131-43-3881036; Fax:131-43-3884092.
n.handels@maastrichtuniversity.nl
16/j.jalz.2015.02.009
e Alzheimer’s Association. Published by Elsevier Inc. All rstage mild cognitive impairment (MCI) for the development
of drugs that prevent conversion to dementia. Despite its
research status, CSF is finding its way in clinical practice
[4] although the decision to adopt it should depend on the
improvement of a patient’s health and, in a resource-
constrained health care system, on cost-utility.
Economic evaluations have evaluated the added value
of pathways from test to treatment (test-treat) of AD bio-
markers [5], although none focussed on the MCI phase
since treatment is absent [6].
By identifying the room for improvement, that is, the ben-
efits when the current practice diagnostic accuracy isights reserved.
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of biomarkers in combination with a disease-modifying treat-
ment (DMT) can be revealed. However, such perfect test does
not exist and estimating the accuracy for predicting the
response of a hypothetical treatment is extremely difficult. A
conventional economic evaluation which only compares a
few alternative strategies would insufficiently reflect all
possible values of diagnostic accuracy that CSF could have.
The position of AD biomarkers in the clinical routine will
nonetheless likely be either to verify AD in patients suspected
of AD (which will cause increased sensitivity at the cost of
specificity) or to rule-out AD (which will cause increased
specificity at the cost of sensitivity, see Supplementary
Fig. 2, available online). Exploring the consequences of these
two strategies over their full range of possible accuracy values
will provide insight in the potential value of biomarkers. The
uprising application of AD biomarkers in practice urges the
need for an early health technology assessment to explore
future scenarios of a biomarker combined with a hypothetical
DMT. This could aid in directing development and possible
applications of AD biomarkers [7].
The aim of this early health technology assessment was to
determine (1) the room of improvement of a perfect CSF
biomarker and (2) the incremental net monetary benefit
(NMB) of a CSF biomarker either in a strategy to verify
an AD diagnosis or to rule-out an AD diagnosis as set by
the current clinical practice diagnostic workup, compared
with current clinical practice in MCI subjects under the con-
dition that in all scenarios a hypothetical DMT for AD is
available after diagnosis, from a societal perspective.2. Methods
2.1. Design
A probabilistic patient-level model was used to synthe-
size available evidence on various disease components and
simulate the difference in lifetime consequences of a group
of individuals with MCI [8,9]. See the online Supplementary
Material for a detailed description of all methods.
Evidence was mainly derived from the Dutch LEARN
study including patients suspected of a primary neurodegen-
erative disease (NDD) [10], the Swedish Kungsholmen proj-
ect which is a general population-based cohort from which
incident MCI and incident dementia cases were filtered
[11], the Dutch MEDICIE study on quality of life and
resource utilization regarding a multidisciplinary diagnostic
and management approach in psychogeriatric patients [12],
literature, and expert opinion.
The room for improvement of a new technological inter-
vention was defined as the benefit when the most optimistic
plausible situation would be realized compared with current
practice [13], that is, it assumes a perfect CSF test that is
100% sensitive and 100% specific. For the incremental
NMB analysis (second aim) the strategy including a CSF
biomarker in its diagnostic workup was compared with thecurrent practice diagnosticworkupwithoutCSF.CSFwas posi-
tioned in two alternative ways as an add-on test to the current
clinical practice diagnostic workup that consisted of a physical,
clinical, and neuropsychological examination, patient and
informal caregiver history, and MRI, in MCI subjects who
visited a memory clinic. First, the CSF test was performed
only if the current practice workup concluded on the presence
of AD (referred to as the “verify AD” strategy, that is, this pre-
vented false positive diagnoses at the cost of false negatives; see
Fig. 1 and Supplementary Fig. 2, and Supplementary Material
Section3.3); second, theCSF testwasperformedonly if the cur-
rent practiceworkup concluded on the absence of AD (referred
to as the “rule-out AD” strategy, that is, this prevented false
negative diagnoses at the cost of false positives; not presented
in Fig. 1). In the control, headroom and both intervention stra-
tegies a hypothetical DMTwas provided if AD was concluded
from the strategy’s diagnostic process. This was modeled as a
one-timeonly treatment decision at incidentMCI.The subject’s
lifetime costs and quality adjusted life years (QALYs) were
compared between the current practice and each of the CSF
strategies. Current available treatments (cholinesterase inhibi-
tors andMemantine)were notmodeled because they are not in-
tended for people suffering from MCI [14].
Annual discount rates for costs and effects were set at 4%
and 1.5%, respectively, according to the Dutch guideline for
pharmacoeconomic research [15].2.2. Model structure
An individual subject simulation model (see Fig. 1) was
developed to model a population of 2000 incident MCI sub-
jects (see Table 1) from a memory clinic setting. Each sub-
ject was quadruplicated; one went through the current
practice control strategy and the other three went through
the intervention strategies (“perfect test” for the room for
improvement analysis, and the “verify AD” and “rule-out
AD” for the incremental NMB analysis). If diagnosed with
AD a hypothetical DMT was applied which, if diagnosed
correctly, delayed conversion to dementia.
Disease progression in the dementia phase was modeled
by the annual change in cognition (Mini-Mental State Exam-
ination or MMSE) and activity of daily living (ADL) (Katz
score). Eventually the model stopped when the subject died
or had been 30 years in the dementia phase. After completion
and populating the model several quality checks were per-
formed (see Supplementary Material Section 5.2).2.3. Model assumptions
A subject’s cause of MCI (AD, other NDD or no NDD)
was assigned at the model start, and never changed because
NDDs were considered nonreversible. All subjects with un-
derlying AD or other NDD were considered at risk of devel-
oping the dementia syndrome. Subjects with no NDD when
presenting at the memory clinic were assumed to never
develop dementia. The hypothetical DMT only affected
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Fig. 1. General model structure for the incremental net monetary benefit analysis reflecting the current practice strategy and the “verify AD” strategy. The
strategy ‘rule-out AD’ was not reflected. This strategy is identical to “verify AD”, except that CSF is performed after clinical practice result TAD2 instead
of TAD1. The perfect test strategy for room for improvement analysis is identical to “verify AD”, except that a perfect test is performed both after clinical practice
TAD1 and after the TAD2 result. Abbreviations: AD, Alzheimer’s disease; CSF, cerebrospinal fluid; Dem, death5 the time to dementia conversion is estimated
lower than the time to death; NDD, neurodegenerative disease; TAD1, result of test workup indicates AD positive; TAD2, result of test workup indicates AD
negative; TTdem, time to dementia; t, time in years.
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vival. No (side effect) stopping rules were modeled.2.4. Test-treat pathway
The diagnostic sensitivity and specificity of the current
practice control strategy to predict hypothetical DMT
response were assumed to be 77% and 68%, respectively.
This was derived from the LEARN study as a best possibleestimate using a clinical prognosis as index test and CSF
beta-amyloid(1–42) total Tau ratio as a reference test (see
Supplementary Material Section 3.3). Because of high un-
certainty around this estimate a more generic approach
that relaxes this point estimate assumption is explained later.
The diagnostic sensitivity and specificity of the interven-
tion strategy to predict hypothetical DMT response was var-
ied over multiple combinations of improved accuracy, which
is explained later. Long-term disease progression could not
Table 1
Participant characteristics of the different data sources cohort studies and the simulated cohort
Characteristic
MCI Dementia
Kungsholmen MEDICIE LEARN Simulated cohort Kungsholmen MEDICIE
Number of measurements 153 57 58 2000 323 144
Age; mean (SD), range 83.4 (4.0), 76.3–97.7 74.9 (6.8), 55–87 68.4 (8.9), 50–89 68.3 (8.9), 37.9–94.7 86.7 (4.1), 78–100 78.7 (6.2), 60–94
Female; % 75% 53% 36% 36% 83% 73%
Years of education;
mean (SD), range
8.5 (3.0), 3–16 N.A. 11.4 (3.5), 6–17 11.6 (3.4), 1–22.4 8.2 (2.9), 3–16 N.A.
MMSE; mean (SD), range 24.4 (2.1), 20–30 23.9 (4.3), 5–29 27.2 (2.2), 22–30 27.1 (2.0), 19.9–30 19.7 (5.0), 0–28 18.6 (5.5), 4–28
Katz; mean (SD), range 0.4 (0.7), 0–4 0.9 (0.7)*, 0–2.7 0.4 (0.8), 0–4 0.51 (0.56), 0–2.6 1.2 (1.7), 0–6 1.3 (0.7), 0–2.8
Abbreviations: MCI, mild cognitive impairment; SD, standard deviation; N.A., not applicable; MMSE, Mini-Mental State Examination.
*Katz is a surrogate Katz score based on the Lawton and the Disability Assessment for Dementia scale (see Supplementary Material Section 3.6).
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therefore assessed in the Swedish Kungsholmen project, a
general population-based cohort design with 6-year
follow-up after incident MCI or incident dementia [11].
The time to death was sampled from the 2012 survival table
from the Dutch national central bureau for statistics.
A hypothetical constant treatment effect of 50% pro-
gression reduction was applied on the time from MCI to
dementia conversion, and on the rate of cognitive
(MMSE) and ADL (Katz score) decline which was based
on similar assumptions on hypothetical DMT efficacy
found in the literature [16].2.5. Costs and health utilities
Cost data were analysed from 1-year resource use inter-
view data of 201 participants from the MEDICIE study
[12,17] (see Supplementary Material Section 3.7). In sum-
mary predictors of 1-year care costs were estimated sepa-
rately for MCI and dementia patients.
The costs in MCI were determined by the Katz score,
whereas Katz and MMSE were the drivers of the costs in de-
mentia patients. The costs of the CSF biomarker per individ-
ual were estimated V211 ($272) based on expert opinion.
Treatment costs were estimated to beV5853 ($7550) per in-
dividual per year based on the assumptions provided by
Sk€oldunger et al. [16]. All costs were expressed in Euros
at 2012 values (at that time, V1.00 was equivalent to US
$1.29 and British £0.81).
Similar to the cost analyses, health-related quality of life
analyses were performed using the Maastricht Evaluation of
a Diagnostic Intervention for Cognitively Impaired Elderly
(MEDICIE) data EQ-5D utility scores [12]. Utilities reflect
the desirability of a health state, measured from 1 (represent-
ing perfect health) to 0 (representing death). Similar to the
cost analyses gender, age, MMSE, a Katz surrogate scale,
and all two-way interactions were tested in a backward
regression (P , .05). Utility in MCI was determined by
the Katz score, whereas it was determined by gender,
MMSE, Katz, and the interaction between gender and
MMSE in dementia patients.Individual disutility due to DMT side effects was esti-
mated by expert opinion (FV) at a constant 0.05 as long
as the treatment was provided. The nonmedical conse-
quences of an incorrect prognosis of dementia were
assumed to be caused by coping with personal decisions
such as incorrect future care planning that was made based
on the wrong information. The disutility of an incorrect AD
positive diagnosis was estimated to be 0.25 for 1 year and
for an incorrect AD negative diagnosis 0.15 for 1 year by
expert opinion (FV).
2.6. Outcome measures
The primary outcome measures were the lifetime average
costs and QALYs over the 2000 individually simulated sub-
jects. These were calculated for both the current practice
control strategy and the strategy of a perfect biomarker
test and aggregated into a single net monetary benefit.
QALYs were multiplied by the maximum Dutch willingness
to pay V80,000 [18] ($103,200) per QALY to express them
in monetary terms.
2.7. Output representation
As explained in the introduction the predictive accuracy of
CSF is unknown and was therefore ranged over all plausible
values. The incremental NMB estimates for each combination
of sensitivity and specificity were averaged and plotted in a
three-axes graph (Fig. 2A). In this graph the horizontal and
depth axis represent a receiver operating characteristic plane.
The combination of 77% sensitivity and 68% specificity rep-
resented the current practice situation and a set of plausible
combinations (see Supplementary Material Section 3.3) of
sensitivity and specificity (see Supplementary Material
Section 3.11) was used to represent the “verify AD” strategy.
Next, an interpolation line was drawn through the sensitivity
and specificity combinations at which the incremental NMB
was zero. This represents the minimally required level of
sensitivity and specificity to ensure cost-effective use of the
CSF intervention when it is used to “verify AD”. An identical
method was used for the “rule-out AD” strategy represented
by Fig. 3A.
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Fig. 2. (A) Left: Incremental net monetary benefit (NMB,V) of the “verifyAD” strategy (i.e., a CSF test was performed if the current practice diagnostic workup
was AD positive). The incremental NMBwas drawn in a Receiver Operator Characteristic plane for each combination of sensitivity (ranging from 0.50 to 0.77)
and specificity (ranging from 0.68 to 1) at a willingness to pay of V80,000 ($103,200). (B) Right: Results of varying the fixed parameters in a univariate sensi-
tivity analysis relative to the base case scenario. The base case scenario consisted of DMT costs 5 V5853 ($7553) and DMT efficacy 5 0.5, AD
prevalence 5 49%, CSF costs 5 V211 ($272), disutility FP and FN only first MCI year, DMT side effects disutility 5 0.05. The dotted black line in the left
and right graph represents the specific combinations of minimal diagnostic sensitivity and specificity at which the CSF intervention was cost-effective in the
base case scenario and thus had a positive incremental NMB. These dotted lines correspond to each other in both graphs. Abbreviations: NMB, net monetary
benefit; AD, Alzheimer’s disease; CSF, cerebrospinal fluid; DMT, disease-modifying treatment; FP, false positive; FN, false negative; MCI, mild cognitive
impairment.
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Fig. 3. (A) Left: Incremental net monetary benefit (NMB, V) of the “rule-out AD” strategy (i.e., a CSF test was performed if the current practice diagnostic
workup was AD negative). The incremental NMBwas drawn in a Receiver Operator Characteristic plane for each combination of sensitivity (ranging from 0.77
to 1) and specificity (ranging from 0.50 to 0.68) at a willingness to pay ofV80,000 ($103,200). (B) Right: Results of varying the fixed parameters in a univariate
sensitivity analysis relative to the base case scenario. The base case scenario consisted of DMT costs 5 V5853 ($7553) and DMT efficacy 5 0.5, AD
prevalence 5 49%, CSF costs 5 V211 ($272), disutility FP and FN only first MCI year, DMT side effects disutility 5 0.05. The dotted black line in the
left and right graph represents the specific combinations of minimal diagnostic sensitivity specificity at which the CSF intervention was cost-effective in the
base case scenario and thus had a positive incremental NMB. These dotted lines correspond to each other in the both graphs. Abbreviations: NMB, net monetary
benefit; AD, Alzheimer’s disease; CSF, cerebrospinal fluid; DMT, disease-modifying treatment; FP, false positive; FN, false negative; MCI, mild cognitive
impairment.
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Fig. 4. (A) Left: Incremental NMB (V) of (1) the intervention strategy where a biomarker was performed if the current practice diagnosis was AD positive
(verify AD) in the bottom right quadrant and (2) the intervention strategy where a biomarker was performed if the current practice diagnosis was AD negative
(rule-out AD) in the left top quadrant. The black dot represents the current practice diagnostic situation (i.e., control strategy). The axes present the relative
sensitivity and specificity change of predicting DMT response due to an AD biomarker relative to current practice. The right top represents a situation with
both improved sensitivity and improved specificity, the left bottom quadrant represents both decreased sensitivity and decreased specificity. These scenarios
fell outside the scope of this article. (B) Right: Results of varying the fixed parameters from the base case scenario (base case DMT costs 5 V5853
($7553) and DMT efficacy 5 0.5, AD prevalence 5 49%, biomarker costs 5 V211 ($272), disutility FP and FN only first MCI year, DMT side
effects disutility 5 0.05) in a univariate sensitivity analysis. The intervention strategy is cost-effective at all combinations of sensitivity and specificity at
the right top area of each line, and not cost-effective at the left bottom area of each line. The dotted black lines in the left and right graph represent the specific
combinations of minimal sensitivity and minimal specificity at which the biomarker intervention was cost-effective in the base case scenario and thus had at a
positive incremental NMB. These lines correspond to each other. Abbreviations: NMB, net monetary benefit; AD, Alzheimer’s disease; DMT, disease-
modifying treatment; FP, false positive; FN, false negative; MCI, mild cognitive impairment.
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sensitivity and specificity is highly uncertain, a more generic
graph was built in Fig. 4. It relies on the relative accuracy
change (from current practice sensitivity and specificity to
the “verify AD” intervention or to the “rule-out AD” sensi-
tivity and specificity) instead of absolute accuracy values.
The generated results can be applied in any situation of con-
trol versus intervention accuracy estimates for any
biomarker in AD under the condition that DMT is available.
This Fig. 4 represents incremental NMB isoquants by incre-
mental changes in sensitivity and specificity, where 0% to
25% increase in specificity was at the cost of 225% to 0%
decrease in sensitivity for the “verify AD” relative to the cur-
rent practice control strategy, and 0% to 25% increase in
sensitivity was at the cost of 225% to 0% decrease in spec-
ificity for the “rule-out AD” relative to the current practice
control strategy.2.8. Uncertainty analyses
In a probabilistic sensitivity analysis, the simulation of
the same 2000 subjects was run 10,000 times using sets of
random parameter values that were drawn to reflect param-
eter uncertainty generating 95% credibility intervals (CI)based on the 2.5 and 97.5 percentile of the 10,000 simula-
tions (see Supplementary Material Section 4.1).
In univariate sensitivity analyses of the room for
improvement the outcomes (i.e., incremental differences
between the control strategy and both intervention strate-
gies) was calculated for scenarios different from the
base case by running the simulation using 2500 iterations
for each scenario (see Supplementary Material Section
4.2). First, a more efficient treatment (DMT
costs 5 V1171 [$1511]; DMT efficacy 5 0.75) and a
less efficient treatment (DMT costs 5 V35,119
[$45,304]; DMT efficacy 5 0.25) were evaluated using
the same estimates as used in the sensitivity analysis of
Sk€oldunger et al. [16]. Next, the outcomes were calcu-
lated for the scenario of a high AD prevalence (75%)
and a low prevalence (25%) estimate. At last, the sce-
narios of 10-folded CSF costs (V2112 ($2724)), longer
disutility of the nonmedical consequences (disutility of
a false positive [FP] and false negative [FN] diagnosis
lasted during whole MCI phase), and higher disutility
of DMT side effects (0.20) were separately evaluated.
These estimates were based on expert opinion (FV) since
in this early stage of Health Technology Assessment
likely estimates were unknown.
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“rule-out AD” strategies are presented by Figs. 2B and 3B,
respectively. By taking other scenarios (the same as
described previously) the specific combinations of
sensitivity and specificity at which the CSF was cost-
effective to “verify AD” or “rule-out AD” changed. This
was expressed by a shift from the dotted black line (that rep-
resents the base case conditions) to the plain colored lines
that represent each of the sensitivity analyses conditions.3. Results
The 2000 simulated MCI subjects had an average (SD)
age of 68.3 (8.9), female proportion of 36%, MMSE of
27.1 (2.0), Katz of 0.51 (0.56), and 49% suffered from
AD pathology. In the current practice, control strategy sub-
jects had on average (95% CI) 8.67 (7.84–9.47) QALYs and
consumed care resources worth V545,712 (465,746 to
636,095) ($703,968). The room for improvement analysis
revealed 0.39 (0.26–0.54) additional QALYs and V33,622
(21,232 to 50,780) ($43,372) savings on average per sub-
ject if a perfect test existed (from 77% sensitivity and
68% specificity in the control strategy (i.e., current practice
diagnostic workup without CSF) for predicting a hypothet-
ical DMT response to 100% sensitivity and 100% speci-
ficity in the perfect CSF test strategy for predicting a
hypothetical DMT response); this resulted in an incremen-
tal NMB of V64,940 (43,995–90,755) ($83,773). Second-
ary outcome measures revealed 2.0 (1.7–2.3) additional
potential beneficial treatment years and dementia conver-
sion occurred 1.3 (1.0–1.7) years later than the current
practice control strategy.
Figs. 2A and 3A represent the incremental NMB of each
combination of sensitivity and specificity for the “verify
AD” and the “rule-out AD” strategies, respectively,
compared with the current practice control strategy.3.1. Univariate sensitivity analysis
The results of the univariate sensitivity analyses on the
room for improvement are presented in Table 2. The incre-
mental NMB of both the current practice and the perfect
test strategy was highest under the condition of a more effi-
cient treatment.
The high and low AD prevalence conditions in the uni-
variate sensitivity analyses on the room for improvement
analysis (Table 2) had only a minor effect on the costs
and QALYs in the base case situation. This can be ex-
plained by the fact that not all subjects with AD survived
up to the point of dementia conversion and thus had not
benefit from treatment. Furthermore, a lower prevalence
of AD implicated an increase of other NDDs (see
Supplementary Table 9) for which treatment was ineffec-
tive. This increased the care resources required for demen-
tia care. Figs. 2B and 3B represent the sensitivity analyses
of the incremental NMB of the “verify AD” and “rule-outAD” strategies. They show that a lower AD prevalence, a
longer disutility due to incorrect diagnoses, and a higher
DMT side effect’s disutility increased the range of
sensitivity and specificity combinations for which CSF
was cost-effective in the “verify AD” strategy. These sce-
narios decreased the range of combinations for which
CSF was cost-effective in the “rule-out AD” strategy. For
the other analyses (more efficient DMT and high AD prev-
alence) this was vice versa. Increased CSF costs slightly
decreased the number of cost-effective combinations. If
DMT was less efficient the “verify AD” strategy was
cost-effective for all combinations of increased specificity
and decreased sensitivity, and the “rule-out AD” strategy
was never cost-effective. These various sensitivity analyses
changed the optimal position of the CSF test due to a shift in
the balance between benefits of preventing over- and under-
treatment. For example, in case of a lower AD prevalence
the number of subjects with overtreatment increased which
emphasizes the importance of a high test specificity to pre-
vent this and keep DMT provision cost-effective (i.e. the
forgone resources and QALY loss due to overtreatment in
a large part of the population were not compensated for
by the benefits of preventing undertreatment of a small
part of the population).
Fig. 4 is similar to Figs. 2 and 3 and presents the situation
of a relative change in sensitivity and specificity due to a
generic biomarker intervention compared with the current
practice situation for both the “verify AD” in the right
bottom quadrant and “rule-out AD” in the left top quadrant
of the graph.4. Discussion
The incremental costs and QALYs between the control
strategy and a perfect test to reveal the room for improve-
ment and between the control strategy and two strategies
in which a CSF biomarker was added to the current clin-
ical practice diagnostic workup (either to verify an AD
diagnosis or a no-AD diagnosis) were estimated by a de-
cision model for MCI assuming a hypothetical DMT was
available. The analysis indicated a room for improvement
of 0.39 (0.26–0.54) QALYs gained and V33,622 (21,232–
50,780) ($43,372) savings on average per subject if a per-
fect test existed compared with current practice. The strat-
egy that used CSF to rule-out AD as set by the current
clinical practice diagnostic workup indicated more poten-
tial benefit than the strategy that used CSF to verify AD,
given the assumptions on a hypothetical DMT effect. This
implies that if such DMT becomes available, biomarker
research should focus on improving the specificity of a
test. Also, this study emphasizes that the full test-
treatment pathway should be considered in biomarker
research because it is mainly not the test itself that im-
proves patient-important outcomes but the downstream
management [19].
Table 2
Mean individual lifetime primary and secondary outcome estimates (based on 2500 model iterations) of the sensitivity analyses of the current practice control
strategy (current practice diagnostic workup without CSF [5cur]) and headroom (CSF test in addition to current practice’s diagnostic workup with 100%
sensitive and 100% specific [5room]), both under the condition of hypothetical DMT
Costs (kV (k$)) QALYs NMB (kV (k$))
Conversion
age
Beneficial
treatment
years
Incremen-tal
NMB (kV (k$))Cur Room Cur Room Cur Room Cur Room Cur Room
Base case* 546 (704) 512 (660) 8.7 9.1 148 (191) 213 (275) 81.1 82.4 6.6 8.6 65 (84)
More efficient treatmenty 491 (633) 452 (583) 8.9 9.4 223 (288) 299 (386) 89.8 93.7 6.6 8.6 76 (98)
Less efficient treatmentz 777 (1002) 741 (956) 8.2 8.4 2122 (2157) 266 (285) 78.2 78.6 6.6 8.6 56 (72)
High AD prevalence (75%) 548 (707) 508 (655) 8.7 9.1 144 (186) 219 (283) 82.2 83.8 10.1 13.1 75 (96)
Low AD prevalence (25%) 540 (697) 512 (660) 8.8 9.1 161 (208) 218 (281) 79.7 80.5 3.5 4.6 56 (73)
High CSF costs (V2112) 546 (704) 514 (663) 8.7 9.1 148 (191) 211 (272) 81.1 82.4 6.6 8.6 63 (81)
Longer disutility FP/FNx 548 (707) 514 (663) 8.1 9.1 99 (128) 211 (272) 81.1 82.4 6.6 8.6 112 (145)
High disutility DMT (0.20) 546 (704) 512 (660) 7.5 8.0 53 (68) 126 (163) 81.0 82.3 6.6 8.6 74 (95)
Abbreviations: CSF, cerebrospinal fluid; DMT, disease-modifying treatment; QALY, quality adjusted life years; NMB, net monetary benefit; AD, Alzheimer’s
disease; FP/FN, false positive/false negative.
*Base case analysis: Annual individual DMT costs 5 V5855 ($7553); DMT efficacy 5 0.5; AD prevalence 5 49%; individual CSF costs 5 V211 ($272);
individual disutility FP 5 .25 only in the first year; disutility FN 5 0.15 only in the first year; disutility side effects 5 0.05.
yDMT costs 5 V1171 ($1511); DMT efficacy 5 0.75.
zDMT costs 5 V35,119 ($45,304); DMT efficacy 5 0.25.
xDisutility of the nonmedical consequences of a FP and FN diagnosis is during the whole mild cognitive impairment phase.
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out AD” strategy is due to the treatment benefits in subjects
with AD. In a post-hoc analysis we retrospectively filtered
the simulated subjects who had AD although were not
diagnosed as such by the current practice control strategy
but who were correctly diagnosed as AD by the CSF test
and treated accordingly (i.e., undertreatment was prevented
by CSF). On average these subjects gained 2.04 (0.90–
3.34) QALYs and V201,099 (93,555–347,341) ($259,418)
savings during lifetime. This was much higher than the
benefits for preventing overtreatment as revealed by a
post-hoc analysis (i.e., wrongly diagnosed as AD and
thus unnecessarily treated with DMT by the current prac-
tice and correctly diagnosed as non-AD due to the CSF
test in the intervention strategy) which were 0.99 QALYs
(0.95–1.03) gained and V67,536 savings (64,409–70,594)
($87,121). The potential benefit in untreated AD subjects
reflects the high demand on care resources in dementia,
which has been estimated between V6614 ($8532) and
V64,426 ($83,110) per year per person [17,20]. In the
decision model DMT diminished the dementia care by
postponing dementia conversion which saved more care
usage costs than the assumed costs to operationalize
DMT itself.
Other studies have evaluated the cost-effectiveness of hy-
pothetical DMT combined with an AD biomarker in MCI
subjects. Sk€oldunger et al. [16] found that DMT was more
cost-effective in a population enriched with more treatment
responders. They extensively elaborated on DMT scenarios
and the impact of mortality on cost-effectiveness but evalu-
ating diagnostic strategies was not their goal. Biasutti et al.
[21] showed that MRI with contrastophore–linker–pharma-
cophore in combination with a hypothetical DMT availableat V1144 ($1476) per year was cost-effective. A similar
result was found by Guo et al. [22] for florbetaben PET.
The latter study included the consequences of a reduced
time to confirmed diagnosis on a delay of institutional
care. Our study estimated the CSF’s room for improvement
and explicitly positions the CSF biomarker as an add-on
clinical practice test to verify or rule-out AD.4.1. Strengths and limitations
The model’s major strengths included explicitly posi-
tioning the CSF diagnostic marker in the current clinical
diagnostic workup and using input evidence that was based
on long-term progression observations. The model was sub-
ject to several limitations. The not knowing of several pa-
rameters is inherent to this early assessment of
technologies. For this reason we deviated from the conven-
tional method of comparing a limited number of alternative
strategies and evaluated any combination of the CSF inter-
vention’s test sensitivity and specificity. It enabled us to
show the most optimal position of a new AD biomarker un-
der various predefined conditions.
The diagnostic process in all strategies was simplified
by not taking into account the time between a first memory
clinic visit and the final diagnosis, a possible false or unde-
termined diagnosis, time to rediagnosis, and the time to a
next doctor visit after dementia conversion. These aspects
are, however, of secondary relevance to the explorative na-
ture of this analysis. Lumbar puncture (headache) side ef-
fects were not taken into account. DMT was simplified
by not taking willingness to receive treatment, stopping
rules due to side effects, or the effect of age on treatment
efficacy into account. The effect of DMT on survival was
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cost-effectiveness, which has been extensively researched
by Sk€oldunger et al. [16]. This resulted in a small propor-
tion (1.6%) surviving dementia for more than 30 years,
which is a limitation of the lifetime generalizability to
the real-world.
The discretization and the truncation of the polynomial
disease progression formulas simplified the long-term pre-
dictions and ensured generalizability. Also, the transforma-
tion of the Disability Assessment for Dementia scale to a
Katz surrogate score using the Lawton scale most likely gen-
erates uncertainty to how well they reflect the actual esti-
mates. The possible error of these simplifications is
identical in both the control and intervention strategies,
although if the Katz transformation led to an overestimation
of its scores, it amplified the Katz related care costs in de-
mentia, which had a higher rate of conversion in the control
strategy. The impact on the conclusions was judged small.
Resource use and utility scores were obtained from a clin-
ical sample and disease progression from a general
population-based sample. Memory clinic subjects are likely
to have more severe problems at diagnosis because the
complaint must be severe enough to initiate a visit. This
might underestimate the CSF benefits because these subjects
miss a window of opportunity for early treatment.
The nonmedical consequences of an early diagnosis on
quality of life were unknown and estimated by expert
opinion. Even if the true value is unknown, it has been
emphasized [23] to include such uncertain estimates. For
example, a related study by McMahon et al. [24] in
demented subjects has included an assumed decrease in
quality of life of 0.05 utility score due to a false diagnosis.5. Conclusions
CSF and related AD biomarkers have the potential to in-
crease care efficiency when DMT becomes available. The
incremental NMB analysis indicated more potential benefit
from a biomarker that was positioned to verify subjects
who are not expected to have AD (i.e., a treatment selection
approach to prevent undertreatment) rather than to verify
subjects expected of AD (a treatment selection approach to
prevent overtreatment) given the assumptions on a hypothet-
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1. Systematic review: Economic evaluations of diag-
nostic techniques have been reviewed by Handels
et al. [5]. We updated this review focussing on ce-
rebrospinal fluid (CSF) and did not retrieve addi-
tional studies. Related studies in positron emission
tomography and magnetic resonance imaging were
used to compare our results to.
2. Interpretation: Similar to other studies we estimated
the potential of biomarkers assuming a hypothetical
disease modifying treatment is available. In addition
to previous studies we explicitly positioned CSF in
the current clinical diagnostic workup and showed
that a strategy of ruling out a clinical diagnosis of
Alzheimer’s disease (AD) indicated more potential
benefit than a strategy of verifying AD, given the as-
sumptions on the hypothetical treatment.
3. Future directions: To expand our findings the
nonmedical consequences of diagnostic testing
should be estimated. This would allow estimating
the value of CSF in current practice mild cognitive
impairment subjects, without available disease modi-
fying treatment and recommend on the position of
CSF in the current diagnostic workup.References
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